{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F98e92272-9715-42b6-8c88-8732ac7f37dc","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"How to Make De Novo a Viable Option for your Medical Device\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/98e92272-9715-42b6-8c88-8732ac7f37dc\"></iframe>","title":"How to Make De Novo a Viable Option for your Medical Device","description":"Is de novo a realistic regulatory pathway? Or, the \u201ckiss of death\u201d for your product? No, to de novo? Think again. Who cares about de novo? We do! Today\u2019s guest is \u201cDr. De Novo \u201c(a.k.a. Mike Drues of Vascular Sciences), who describes how to make de novo a viable option for your medical device.  \n\nSome of the highlights of the show include:\n \n\u25cf\tFor years, use of de novo was rare; fewer than five devices were brought to market. MDUFA stats state FDA received 56 de novos in 2018; 18 in 2019.\n\u25cf\tCongress deserves credit for changing the law to make de novos more attractive to companies. De novo nuances became less problematic and challenging.\n\u25cf\tMike\u2019s public prediction in 2012 came true. De novo pathway has increased in importance, popularity, and usage; but still pale in comparison to 510(k).\n\u25cf\tDe novo is advantageous option for medical device technology, especially mobile medical apps, imaging, and in-vitro diagnostics (IVDs). \n\u25cf\tRather than focusing on options from a regulatory pathway, analyze and account for who at the agency will be the recipient due to their de novo experience.\n\u25cf\t510(k) vs. De Novo: Is device new and novel? Or, similar in technology and labeling to another device on the market?\n\u25cf\tDe Novo: Applicable for lower than Class III medical devices; 510(k) requires substantial equivalence and risk; de novo only needs risk mitigation strategy.\n\u25cf\tFDA\u2019s review time of de novo submissions average six to eight months, while 510(k) submissions take three to four months.","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/594e3dd0-98c9-4fe4-8982-8da79f97d5dc/d6a95da0-379c-4954-b1ba-efd55bd1fe4e.jpg"}